# FlowMedica

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/flowmedica

- Industry: Medical Devices & Equipment
- Headquarters: Fremont, US
- Website: www.flowmedica.com
- Total disclosed funding: $21M
- Latest round: Series D (Nov 8, 2005)
- Investors on record: 6

## About

FlowMedica is a healthcare company focused on advancing cardiovascular and peripheral vascular therapies through innovative medical devices and solutions.FlowMedica specializes in medical device solutions for cardiovascular and peripheral vascular applications. The company was acquired by AngioDynamics, Inc. in January 2009 for USD 1.75 mn. FlowMedica operates out of Fremont, US, and has been involved in 4 deals since its inception. The founder's prior experience is not documented in available sources.FlowMedica provides innovative medical device solutions aimed at enhancing treatments for cardiovascular diseases and peripheral vascular conditions. Their offerings include specialized devices designed to improve patient outcomes in minimally invasive procedures, targeting healthcare providers looking to optimize care delivery in these critical areas.FlowMedica generates revenue through the sales of its medical devices tailored for cardiovascular and peripheral vascular applications. The primary revenue streams come from direct sales to hospitals and clinics, focusing on advanced technologies that address specific medical needs in the healthcare sector. Precise pricing details are maintained as proprietary information, but the company emphasizes delivering value through their specialized product offerings.FlowMedica plans to leverage its recent acquisition funding for expanding its product line and entering new geographic markets. The company is focusing on developing new medical device innovations with anticipated launches in the next 12 to 24 months. Future expansion efforts are directed towards key markets in North America and Europe, aiming to establish a stronger presence by 2025. The investment from AngioDynamics is expected to support these growth initiatives, enhancing research and development capabilities.

## Funding rounds

- Series D, Nov 8, 2005, $15M — AAC Capital Partners, Oxford Bioscience Partners, De Novo Ventures, Medica Venture Partners, Palo Alto Investors
- Series C, Sep 15, 2004, $5.6M — AAC Capital Partners, Oxford Bioscience Partners, Mi3 Venture Partners, Medica Venture Partners

## Investors

- AAC Capital Partners (https://capitalatlas.ai/funds/aac-capital-partners) — Series C, Series D
- Oxford Bioscience Partners (https://capitalatlas.ai/funds/oxford-bioscience-partners) — Series C, Series D
- Mi3 Venture Partners (https://capitalatlas.ai/funds/mi3-venture-partners) — Series C
- Medica Venture Partners (https://capitalatlas.ai/funds/medica-venture-partners) — Series C, Series D
- De Novo Ventures (https://capitalatlas.ai/funds/de-novo-ventures) — Series D
- Palo Alto Investors (https://capitalatlas.ai/funds/palo-alto-investors) — Series D